These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular genetics of meningiomas: from basic research to potential clinical applications. Simon M; Boström JP; Hartmann C Neurosurgery; 2007 May; 60(5):787-98; discussion 787-98. PubMed ID: 17460514 [TBL] [Abstract][Full Text] [Related]
4. [Meningiomas: new prognostic factors]. Sanz Esponera J An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599 [TBL] [Abstract][Full Text] [Related]
5. [Genetics and molecular biology of neurinoma and meningioma]. Fontaine B Rev Neurol (Paris); 1993; 149(1):4-13. PubMed ID: 8337561 [TBL] [Abstract][Full Text] [Related]
6. Meningioma: the impact of new techniques for the diagnosis and prognosis. Scarpelli M; Mazzucchelli R; Colanzi P Adv Clin Path; 1997 Apr; 1(2):149-153. PubMed ID: 10352478 [TBL] [Abstract][Full Text] [Related]
7. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125 [TBL] [Abstract][Full Text] [Related]
9. [Neurologic diseases due to alterations in oncogenes and tumor suppressing genes]. Bello MJ; Rey JA Neurologia; 1995 Dec; 10 Suppl 1():20-31. PubMed ID: 8838556 [TBL] [Abstract][Full Text] [Related]
11. Meningiomas in 2009: controversies and future challenges. Campbell BA; Jhamb A; Maguire JA; Toyota B; Ma R Am J Clin Oncol; 2009 Feb; 32(1):73-85. PubMed ID: 19194129 [TBL] [Abstract][Full Text] [Related]
12. Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Pfisterer WK; Hendricks WP; Scheck AC; Nieman RA; Birkner TH; Krampla WW; Preul MC Neurosurgery; 2007 Nov; 61(5):1048-59; discussion 1060-1. PubMed ID: 18091281 [TBL] [Abstract][Full Text] [Related]
13. Genomic deletions at 1p and 14q are associated with an abnormal cDNA microarray gene expression pattern in meningiomas but not in schwannomas. Martínez-Glez V; Alvarez L; Franco-Hernández C; Torres-Martin M; de Campos JM; Isla A; Vaquero J; Lassaletta L; Castresana JS; Casartelli C; Rey JA Cancer Genet Cytogenet; 2010 Jan; 196(1):1-6. PubMed ID: 19963129 [TBL] [Abstract][Full Text] [Related]
14. Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Ketter R; Rahnenführer J; Henn W; Kim YJ; Feiden W; Steudel WI; Zang KD; Urbschat S Neurosurgery; 2008 Jan; 62(1):61-9; discussion 69-70. PubMed ID: 18300892 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of NF2 gene deletion in pediatric meningiomas using chromogenic in situ hybridization. Begnami MD; Rushing EJ; Santi M; Quezado M Int J Surg Pathol; 2007 Apr; 15(2):110-5. PubMed ID: 17478763 [TBL] [Abstract][Full Text] [Related]
17. [The concept of suppressor genes in the molecular biology of central nervous system tumors]. el-Azouzi M; Black PM Neurochirurgie; 1989; 35(4):201-8. PubMed ID: 2575713 [TBL] [Abstract][Full Text] [Related]